Chemed (CHE) Receives a Buy from Bank of America Securities
In a report released today, Joanna Gajuk from Bank of America Securities maintained a Buy rating on Chemed, with a price target of $595.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Gajuk is a 2-star analyst with an average return of 0.2% and a 49.78% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Acadia Healthcare, and Brookdale Senior Living.
In a report released on December 8, Jefferies also maintained a Buy rating on the stock with a $550.00 price target.
Based on Chemed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $624.9 million and a net profit of $64.24 million. In comparison, last year the company earned a revenue of $606.18 million and had a net profit of $75.78 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CHE in relation to earlier this year. Last month, Kevin J. McNamara, the President & CEO of CHE sold 2,000.00 shares for a total of $875,100.00.
Read More on CHE:
